Skip to main content
OpenTrials

Clinical trial condition

Recurrent Platinum-Resistant Ovarian Carcinoma

Explore clinical trials studying Recurrent Platinum-Resistant Ovarian Carcinoma. Study availability and eligibility vary by location and protocol.

9 public trials 5 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Platinum-Resistant Ovarian Carcinoma trial results

Recruiting

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

NCT04633239

Conditions
Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 27 locations
View Trial Details
Recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

NCT05950464

Conditions
Endometrial Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +18 more
Locations
  • Augusta University Medical Center Augusta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States
View all 14 locations
View Trial Details
Recruiting

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

NCT06964009

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +16 more
Locations
  • Beth Israel Deaconess Medical Center (BIDMC) Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02839707

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +33 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 920 locations
View Trial Details
Active, Not Recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

NCT04739800

Conditions
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, +47 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 392 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

NCT05691504

Conditions
Adnexal Diseases, Advanced Endometrial Carcinoma, Carcinosarcoma, +28 more
Locations
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
View Trial Details

Related conditions